3-Drugs Chemotherapy Regimen for G3 PanNENs with Ki67 below 55%: Single Institution Experience

#1396

Introduction: To date no standard regimen of chemotherapy (CTH) is universally approved for advanced pancreatic neuroendocrine neoplasms (PanNENs) with Ki67<55% and no predictive selection criteria is available.

Aim(s): To retrospectively assess the outcomes obtained with CHT in PanNENs with Ki67<55%.

Materials and methods: We retrospectively reviewed data from unresectable PanNENs patients (P) who received CHT during 2011-2015. Ki67% > 55% or mixed hystological type were excluded. P underwent CHT with STZ/5FU (2C) or DTIC-5FU-CDDP (3C) and were separately analyzed.

Conference: 13th Annual ENETSConcerence (2016)

Presenting Author: Grego E

Authors: Grego E, Cingarlini S, Ortolani S, Crosara S, De Robertis R,

Keywords: 3-drugs chemotherapy regimen, pancreatic nets, ki-67% <55%,

To read the full abstract, please log into your ENETS Member account.